Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2008

01.02.2008

Genetic counseling for inherited thrombophilias

verfasst von: Elizabeth A. Varga

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Genetic testing for inherited thrombophilia, including mutation analysis for factor V Leiden and prothrombin G20210A, is commonly performed. Yet, tests for inherited thrombophilia are frequently ordered inappropriately, and without proper counseling about the risks, benefits and limitations of testing. Genetic counselors are uniquely trained to help people understand and adapt to medical, psychological and familial implications of genetic contributions to disease. In the context of thrombophilia, genetic counselors may serve as a resource to other clinicians to: (a) identify individuals and families at increased risk for inherited thrombophilia, (b) offer and explain testing to patients and families, as appropriate, (c) facilitate patient-focused decision-making and informed consent prior to testing, (d) interpret test results, (e) explain inheritance patterns and discuss implications of thrombophilia for family members and (f) provide education and support resources. This article will provide insight into the training and roles of genetic counselors, review indications for thrombophilia testing, and highlight specific issues related to genetic testing, including genetic discrimination concerns.
Literatur
1.
Zurück zum Zitat Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ et al (2005) Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med 7(6):444–453PubMed Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ et al (2005) Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med 7(6):444–453PubMed
2.
Zurück zum Zitat Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA (2001) American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 3(2):139–148PubMed Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA (2001) American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 3(2):139–148PubMed
3.
Zurück zum Zitat McGlennen RC, Key NS (2002) Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med 126(11):1319–1325PubMed McGlennen RC, Key NS (2002) Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med 126(11):1319–1325PubMed
4.
Zurück zum Zitat Press RD, Bauer KA, Kujovich JL, Heit JA (2002) Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 126(11):1304–1318PubMed Press RD, Bauer KA, Kujovich JL, Heit JA (2002) Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 126(11):1304–1318PubMed
6.
Zurück zum Zitat Saukko PM, Richards S, Shepherd MH, Campbell J (2006) Are genetic tests exceptional? Lessons from a qualitative study on thrombophilia. Soc Sci Med 63(7):1947–1959PubMedCrossRef Saukko PM, Richards S, Shepherd MH, Campbell J (2006) Are genetic tests exceptional? Lessons from a qualitative study on thrombophilia. Soc Sci Med 63(7):1947–1959PubMedCrossRef
7.
Zurück zum Zitat Bank I, Scavenius MP, Buller HR, Middeldorp S (2004) Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res 113(1):7–12PubMedCrossRef Bank I, Scavenius MP, Buller HR, Middeldorp S (2004) Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res 113(1):7–12PubMedCrossRef
8.
Zurück zum Zitat Hellmann EA, Leslie ND, Moll S (2003) Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost 1(11):2335–2339PubMedCrossRef Hellmann EA, Leslie ND, Moll S (2003) Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost 1(11):2335–2339PubMedCrossRef
9.
10.
Zurück zum Zitat Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G (2003) Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med 163(9):1105–1109PubMedCrossRef Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G (2003) Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med 163(9):1105–1109PubMedCrossRef
11.
Zurück zum Zitat Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F (1997) Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 78(6):1480–1483PubMed Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F (1997) Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 78(6):1480–1483PubMed
12.
Zurück zum Zitat Makris M, Rosendaal FR, Preston FE (1997) Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl 740:9–15PubMed Makris M, Rosendaal FR, Preston FE (1997) Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl 740:9–15PubMed
13.
Zurück zum Zitat Seligsohn U, Zivelin A (1997) Thrombophilia as a multigenic disorder. Thromb Haemost 78(1):297–301PubMed Seligsohn U, Zivelin A (1997) Thrombophilia as a multigenic disorder. Thromb Haemost 78(1):297–301PubMed
14.
Zurück zum Zitat Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA (2001) American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 3(2):139–148PubMedCrossRef Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA (2001) American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 3(2):139–148PubMedCrossRef
15.
Zurück zum Zitat Press RD, Bauer KA, Kujovich JL, Heit JA (2002) Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 126(11):1304–1318PubMed Press RD, Bauer KA, Kujovich JL, Heit JA (2002) Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 126(11):1304–1318PubMed
16.
Zurück zum Zitat Brenner BR, Nowak-Gottl U, Kosch A, Manco-Johnson M, Laposata M (2002) Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch Pathol Lab Med 126(11):1296–1303PubMed Brenner BR, Nowak-Gottl U, Kosch A, Manco-Johnson M, Laposata M (2002) Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch Pathol Lab Med 126(11):1296–1303PubMed
17.
Zurück zum Zitat Laurino MY, Bennett RL, Saraiya DS, Baumeister L, Doyle DL, Leppig K et al (2005) Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the National Society of Genetic Counselors. J Genet Couns 14(3):165–181PubMedCrossRef Laurino MY, Bennett RL, Saraiya DS, Baumeister L, Doyle DL, Leppig K et al (2005) Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the National Society of Genetic Counselors. J Genet Couns 14(3):165–181PubMedCrossRef
18.
Zurück zum Zitat Wu O, Robertson L, Twaddle S, Lowe GDO, Clark P, Greaves M et al (2006) Screening for thrombophilia in high-risk situations: systemic review and cost-effectiveness analysis. The Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 10(11):1–110PubMed Wu O, Robertson L, Twaddle S, Lowe GDO, Clark P, Greaves M et al (2006) Screening for thrombophilia in high-risk situations: systemic review and cost-effectiveness analysis. The Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 10(11):1–110PubMed
19.
Zurück zum Zitat Reich LM, Bower M, Key NS (2003) Role of the geneticist in testing and counseling for inherited thrombophilia. Genet Med 5(3):133–143PubMed Reich LM, Bower M, Key NS (2003) Role of the geneticist in testing and counseling for inherited thrombophilia. Genet Med 5(3):133–143PubMed
20.
Zurück zum Zitat Varga, EA (2007) Inherited thrombophilias: key points for genetic counseling. J Genet Couns, May 1 [Epub ahead of print] Varga, EA (2007) Inherited thrombophilias: key points for genetic counseling. J Genet Couns, May 1 [Epub ahead of print]
Metadaten
Titel
Genetic counseling for inherited thrombophilias
verfasst von
Elizabeth A. Varga
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2008
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0056-2

Weitere Artikel der Ausgabe 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.